Smith, M.; Pütz, B.; Auer, D.; Fahrmeir, L.: Assessing brain activity through spatial Bayesian variable selection. NeuroImage 20 (2), pp. 802 - 815 (2003)

Stevens, S. L.; Shaw, T. E.; Dykhuizen, E.; Lessov, N. S.; Hill, J. K.; Wurst, W.; Stenzel-Poore, M. P.: Reduced cerebral injury in CRH-R1 deficient mice after focal ischemia: A potential link to microglia and atrocytes that express CRH-R1. Journal of Cerebral Blood Flow and Metabolism 23 (10), pp. 1151 - 1159 (2003)

Trenkwalder, C.; Seidel, V. C.; Kazenwadel, J.; Wetter, T. C.; Oertel, W.; Selzer, R.; Kohnen, R.: One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome? Movement Disorders 18 (10), pp. 1184 - 1189 (2003)

Wetter, T. C.; Winkelmann, J.; Eisensehr, I.: Current treatment options for restless legs syndrome. Expert Opinion on Pharmacotherapy 4 (10), pp. 1727 - 1738 (2003)

Yushchenko, M.; Mader, M.; Elitok, E.; Bitsch, A.; Dressel, A.; Tumani, H.; Bogumil, T.; Kitze, B.; Poser, S.; Weber, F.: Interferon-beta-1b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. Journal of Neurology 250 (10), pp. 1224 - 1228 (2003)

Zimmermann, P.; Wittchen, H. U.; Höfler, M.; Pfister, H.; Kessler, R. C.; Lieb, R.: Primary anxiety disorders and the development of subsequent alcohol use disorders: a 4-year community study of adolescents and young adults. Psychological Medicine 33 (7), pp. 1211 - 1222 (2003)

Kuchenbauer, F.; Theodoropoulou, M.; Hopfner, U.; Stalla, J.; Renner, U.; Tonn, J. C.; Low, M. J.; Arzt, E.; Stalla, G. K.; Páez-Pereda, M.: Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development. Molecular and Cellular Endocrinology 207 (1-2), pp. 13 - 20 (2003)

Wichniak, A.; Brunner, H.; Friess, E.; Pollmächer, T.: Successful suppression of cataplectic attacks with tramadol. Neurology 61 (6), pp. 864 - 865 (2003)

Ackl, N.; Schreiber, Y. A.; Ising, M.; Sonntag, A.; Auer, D. P.: Evaluation of H-1-MRS as diagnostic marker for mild cognitive impairment and dementia. Pharmacopsychiatry 36 (5), p. 210 - 210 (2003)

Adena, S. M.; Ising, M.; Lauer, C.; Holsboer, F.; Modell, S.: The effects of RS-86 on sleep with respect to depression and HLA-type. Pharmacopsychiatry 36 (5), p. 210 - 210 (2003)

Antonijevic, I. A.; Murck, H.; Frieboes, R. M.; Steiger, A.: Gender differences in sleep endocrine regulation following administration of growth-hormone releasing hormone (GHRH) - relevance for the pathophysiology of major depression. Pharmacopsychiatry 36 (5), p. 211 - 211 (2003)

Barkow, K.; Maier, W.; Üstün, T. B.; Gansicke, M.; Wittchen, H. U.; Heun, R.: Risk factors for depression at 12-month follow-up in adult primary health care patients with major depression: an international prospective study. Journal of Affective Disorders 76 (1-3), pp. 157 - 169 (2003)

Bayatti, N.; Zschocke, J.; Behl, C.: Brain region-specific neuroprotective action and signaling of corticotropin-releasing hormone in primary neurons. Endocrinology 144 (9), pp. 4051 - 4060 (2003)

Brunner, J.; Bronisch, T.; Pfister, H.; Jacobi, F.; Wittchen, H. U.: High cholesterol, triglycerides, and body-mass index in suicide attempters with major depression. Pharmacopsychiatry 36 (5), p. 216 - 216 (2003)

Brunner, J.; Ising, M.; Binder, E. B.; Künzel, H. E.; Nickel, T.; Pfennig, A.; Kern, N.; Fuchs, B.; Majer, M.; Holsboer, F. et al.; Modell, S.: Prediction of response to antidepressant monotherapy. Pharmacopsychiatry 36 (5), p. 216 - 216 (2003)

Bschor, T.; Ising, M.; Bauer, M.; Lewitzka, U.; Skerstupeit, M.; Müller-Oerlinghausen, B.; Baethge, C.: Time in depression and mania: Running fast or running slow? A computer based, controlled study of 93 depressed, manic and control subjects. Pharmacopsychiatry 36 (5), p. 216 - 216 (2003)

Czisch, M.; Wehrle, R.; Kaufmann, C.; Wetter, T. C.; Holsboer, F.; Pollmächer, T.; Auer, D. P.: Thalamo-cortical synchronization across the sleep-wake cycle: A combined fMRI/EEG study. Pharmacopsychiatry 36 (5), p. 218 - 218 (2003)

Dalal, M. A.; Schuld, A.; Pollmächer, T.: Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects. Pharmacopsychiatry 36 (5), p. 218 - 218 (2003)

Deiml, T.; Haseneder, R.; Zieglgänsberger, W.; Baghai, T. C.; Eser, D.; Schule, C.; Ella, R.; Eisensamer, B.; Rupprecht, R.; Hapfelmeier, G.: alpha-thujone reduces 5-HT3 receptor activity by an effect on the agonist-induced desensitization. Pharmacopsychiatry 36 (5), p. 219 - 219 (2003)

Deussing, J.; Breu, J.; Binder, E. B.; Ohl, F.; Holsboer, F.; Wurst, W.: Addressing in vivo functions of urocortin III, a novel member of the CRH family of neuropeptides. Pharmacopsychiatry 36 (5), p. 221 - 221 (2003)